Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 2:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 169 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: APS Clear all
Completed Not applicable Interventional

Axumin PETMRI Imaging Following Focal Cryo-ablation (FCA)

NCT04009083
View directory record Official record
Conditions
Prostate Cancer
Interventions
Standard of Care MRI, Fluciclovine PET scan added to MRI
Device · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Sep 10, 2026, 2:03 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

EmpowHer is Prevention Curriculum for Youth Ages 10-15 Years.

NCT06217809
View directory record Official record
Conditions
Abstinence, Sex
Interventions
The intervention curriculum addresses sexual activity, abstinence, and adulthood preparation topics.
Behavioral
Lead sponsor
Alternatives For Girls
Other
Eligibility
10 Years to 15 Years
Enrollment
552 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Sep 10, 2026, 2:03 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Use Surveillance Technology to Reduce Elder Abuse Recidivism

NCT04563728
View directory record Official record
Conditions
Elder Abuse, Self Neglect, Aging, Domestic Abuse
Interventions
Surveillance camera(s)
Behavioral
Lead sponsor
Rutgers University
Other
Eligibility
60 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Sep 10, 2026, 2:03 AM EDT
Terminated Phase 2 Interventional Results available

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

NCT01681433
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castrate-Resistant Prostate Cancer, PSA
Interventions
OGX-427, Abiraterone Acetate, Prednisone
Drug
Lead sponsor
Costantine Albany
Other
Eligibility
18 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
10
States / cities
Marina del Rey, California • Bloomington, Indiana • Goshen, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2022 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

NCT04530552
View directory record Official record
Conditions
Localized Prostate Carcinoma, Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Interventions
Apalutamide, Biospecimen Collection, Quality-of-Life Assessment
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Tucson, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

NCT01046916
View directory record Official record
Conditions
Prostate Cancer
Interventions
TAK-700
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Ann Arbor, Michigan • Portland, Oregon • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 10, 2026, 2:03 AM EDT
Terminated Phase 4 Interventional

iPACK Block With Dexamethasone For Total Knee Replacement

NCT04917055
View directory record Official record
Conditions
Knee Osteoarthritis, Acute Pain, Anesthesia, Local, Regional Anesthesia
Interventions
ropivacaine 0.25% with epinephrine and 6mg dexamethasone, Saline
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

NCT01171898
View directory record Official record
Conditions
Prostate Cancer
Interventions
ARN-509 (Phase 1), ARN-509 (Phase 2)
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris

NCT00714454
View directory record Official record
Conditions
Acne Vulgaris
Interventions
APS Topical Lotion, Placebo
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 39 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2008 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Not applicable Interventional

The Utility of Pretracheal Stethoscope in Detecting Respiratory Abnormalities in Sedated Children

NCT01957566
View directory record Official record
Conditions
Sedation
Interventions
APS
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
2 Years to 18 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Sep 10, 2026, 2:03 AM EDT
Withdrawn Phase 4 Interventional

Improving Pain Management After Total Shoulder Replacement Using Bupivacaine Liposome

NCT04134442
View directory record Official record
Conditions
Osteoarthritis of the Shoulder, Shoulder Pain, Pain, Postoperative
Interventions
Bupivacaine Liposome Injection, Standard Therapy
Drug · Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Sep 10, 2026, 2:03 AM EDT
Not listed Phase 2 Interventional

Extension to Study of Effects of Pomegranate Extract on Rising PSA Levels After Primary Therapy for Prostate Cancer

NCT00732043
View directory record Official record
Conditions
Prostate Cancer
Interventions
pomegranate extract, pomegranate juice, placebo
Dietary Supplement
Lead sponsor
Roll International Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Sep 10, 2026, 2:03 AM EDT
Recruiting No phase listed Observational

The APS Phenotyping Study

NCT06521502
View directory record Official record
Conditions
ARDS, Sepsis, Pneumonia
Interventions
Blood collection, Urine Collection, Nasal, oral, and rectal swabs, Stool collection, Heat Moisture Exchange Filter collection, Tracheal Aspirate sample collection, Non-bronchoscopic bronchoalveolar lavage (NBBAL), Surveys, Short physical performance battery, Hand grip strength, CNS Vital Signs, Muscle Ultrasound, Muscle Strength, Spirometry, Lung Diffusion Testing (DLCO), Chest CT Scan
Other · Procedure · Radiation
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
20
States / cities
Fresno, California • Palo Alto, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 10, 2026, 2:03 AM EDT
Completed No phase listed Observational

Active Surveillance in Prostate Cancer

NCT00490763
View directory record Official record
Conditions
Prostate Cancer
Interventions
Survey
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
1,139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 10, 2026, 2:03 AM EDT
Completed No phase listed Observational

Frequency of Prostate-Specific Antigen Screening in African American Men in the San Francisco Area

NCT00702104
View directory record Official record
Conditions
Prostate Cancer
Interventions
survey administration
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
35 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Sep 10, 2026, 2:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07190300
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
Tulmimetostat, Darolutamide, Abiraterone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • Iowa City, Iowa • Westwood, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer

NCT00658697
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Bevacizumab, ADT, Bicalutamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Sep 10, 2026, 2:03 AM EDT
Not listed Phase 2 Interventional

68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer

NCT02282137
View directory record Official record
Conditions
Prostate Cancer
Interventions
68Ga-PSMA
Drug
Lead sponsor
Ebrahim Delpassand
Other
Eligibility
18 Years and older · Male only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 10, 2026, 2:03 AM EDT
Terminated Phase 3 Interventional Results available

Muscadine Plus (MPX) In Men With Prostate Cancer

NCT03535675
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Muscadine Plus, Placebos
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
13
States / cities
Duarte, California • La Jolla, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 10, 2026, 2:03 AM EDT
Terminated No phase listed Observational

Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided Biopsy

NCT05872503
View directory record Official record
Conditions
Prostate Specific Antigens, Positive Digital Rectal Examination, Strong Family History of Prostate Cancer, Prostatic Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
35 Years to 120 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

NCT00020254
View directory record Official record
Conditions
Prostate Cancer
Interventions
aldesleukin, recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, recombinant vaccinia-B7.1 vaccine, sargramostim, nilutamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 10, 2026, 2:03 AM EDT
Recruiting No phase listed Observational

Flotufolastat F 18 PET in Men With Very Low PSA Recurrence

NCT06862856
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma), Prostate Specific Antigen
Interventions
Positron Emission Tomography (PET)
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 10, 2026, 2:03 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History of Individuals With Immune System Problems That Lead to Fungal Infections

NCT01386437
View directory record Official record
Conditions
Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis, CARD9, APECED
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 99 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 10, 2026, 2:03 AM EDT
Completed Not applicable Interventional

MindVybe tVNS/APS for Wellbeing in Breast Cancer Survivors

NCT07782866
View directory record Official record
Conditions
Breast Cancer
Interventions
Transcutaneous vagus nerve and acupuncture point stimulation
Device
Lead sponsor
The Healing Consciousness Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Meadowbrook, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 10, 2026, 2:03 AM EDT